“The programme looks excellent” Prof Karol Sikora, Global Clinical Expert - , AstraZeneca

Cancer Drug Development: New Directions and Challenges 10th & 11th March 2003, The Hatton,

Gain an insight from leaders in the field: • Prof Karol Sikora, Global Clinical Expert - Cancer, AstraZeneca • Dr Pearl Huang, Director, , GlaxoSmithKline • Dr George Blackledge, Vice President, Medical Director, Oncology, AstraZeneca • Dr Giorgio Massimini, Director, Clinical Oncology, Pharmacia • Dr Paolo Paoletti, Vice President, Medical – Oncology, ALIMTA Product Team Leader, Lilly • Dr Paul Quartey, Medical Director, Schering-Plough • Dr Juergen Hammer, Head, Bioinformatics, Genetics & Genomics, Roche • Dr Peter Traxler, Senior Scientist, Research Manager, Novartis • Dr Jonathan Allis, Vice President, Imaging Technology Group, Amersham Health • Dr Jeffrey Ulmer, Senior Director, Chiron • Dr Leonard Post, Senior Vice President, Research & Development, Onyx Pharmaceuticals • Prof Stephen Jackson, Deputy Director, Wellcome Trust / Cancer Research UK Institute • Prof Ian Judson, Professor, Cancer Pharmacology, Honourary Consultant Medical Oncologist, Institute of Cancer Research / Royal Marsden NHS Trust Programme Highlights • TRANSLATIONAL : keep up to date with the latest technology • REGULATIONS: assess new ways of satisfying requirements • IMMUNE RESPONSE EXPLOITATION: review the current approaches • TARGETED DRUGS: focus on the new directions • NETWORKING: exchange ideas with leaders in the field

PLUS A HALF DAY EXECUTIVE BRIEFING Novel Immunotherapeutic Vaccine Platform 12th March 2003, The Hatton, London. In association with

www.smi-online.co.uk/cancerdrugs.asp Register online and receive full information on all of SMi’s conferences Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

50% DISCOUNT Academic Researchers receive 50% discount

Supported by www.smi-online.co.uk/cancerdrugs.asp Register online and receive full information on all of SMi’s conferences Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

8.30 Registration & Coffee 12.40 Lunch

9.00 Chairman's Opening Remarks TRANSLATIONAL MEDICINE Prof Karol Sikora, Global Clinical Expert - Cancer, AstraZeneca

OPENING ADDRESS HIGH-THROUGHPUT TARGET IDENTIFICATION AND ASSESSMENT TRANSLATIONAL CANCER RESEARCH 2.00 Benefits of “Process Biology”, a modular target

10th March 2003 March 10th 9.10 The key to the future assessment approach • The paradigm shift in cancer drug development • The new order of corporate research organisation • Need for operational improvements of the target • Bridging the academic - industrial divide assessment process • Harnessing innovation in biomarkers, surrogates and imaging • Expression analysis technologies for drug discovery • Creating diagnostic capability to package with new Day One • Prioritising most likely drug candidates therapeutics • Knowledge discovery in an integrated environment • Creating centres of excellence in translational research Prof Karol Sikora, Global Clinical Expert - Cancer, AstraZeneca • Integrating traditional and in silico approaches Dr Juergen Hammer, Head, Bioinformatics, Genetics & REGULATORY MATTERS, CLINICAL TRIALS AND PUBLIC POLICY Genomics, Roche

WHAT ARE THE CRITERIA? IMAGING RESEARCH PROGRAMMES 9.40 Iressa – the first of a new type of cancer medicine • Clinical benefits 2.40 Bringing diagnosis and therapy together • Results of clinical trials • Identifying new molecular diagnostic products • Tumour response rates required for regulatory approval • Acceleration of research decisions • Convincing controls • Imaging technology • Compassionate use programmes • Facilitating early approval of new therapeutics Dr George Blackledge, Vice President, Medical Director, Oncology, AstraZeneca • Application to treatment of cancer • Future potential for finding new and powerful diagnostic and MEETING THE CHALLENGE OF PUBLIC POLICY therapeutic products 10.20 Getting it right with NICE Dr Jonathan Allis, Vice President, Imaging Technology Group, • Mode of action of Caelyx® in fighting cancer Amersham Health • Patient selection for treatment • Importance of cost issues • Benefits of cost issues regarding numbers of patients eligible 3.20 Afternoon Tea for treatment • Efficacy and tolerability factors ANGIOGENESIS • Ease of administration Dr Paul Quartey, Medical Director, Schering-Plough MULTIPLE MYELOMA AND MYELOPROLIFERATIVE DISORDERS 11.00 Morning Coffee 3.40 The ImIDs • Thalidomide NEW APPROACHES TO CLINICAL DEVELOPMENT • Celgene’s STEPS programme 11.20 New drugs, new criteria • Maximum tolerated dose • Multiple myeloma and myeloproliferative disorders • Biological effective dose • Myelofibrosis with myeloid metaplasia • Accurate dose:response information • REVIMID • How significant is shrinkage / no shrinkage? • ACTIMID • Reliability of tumour markers • Future directions • Assessment of combination therapy of new drugs with traditional ones Dr Jerome Zeldis, Chief Medical Officer, Vice President, Medical Dr Giorgio Massimini, Director, Clinical Oncology, Pharmacia Affairs, Celgene

NEW ANTICANCER DRUGS INNOVATIVE CANCER THERAPY 12.00 Impact of changing targets on trial design • Preclinical aspects of new drug development – developing pharmacodynamic assays as an integral part of the preclinical 4.20 ONCOLYTIC VIRUSES package • Advantages of adenovirus as platform • Recently identified new targets • Exploiting the abnormal p53 and RB pathways in malignant • Development of mechanism-based clinical trials cells • Defining the Optimum Biological Dose – is this a realistic goal? • Specificities of adenoviruses ONYX-015 and ONYX-411 • Impact of new targets on conventional concepts of Phase I / II trials • Clinical experience : safety and efficacy • Imatinib in gastrointestinal stromal tumour – lessons for future • Armed therapeutic viruses : oncolytic adenoviruses as vectors molecular targeted therapies for transgene delivery • Satisfying the regulatory authorities – are phase II trials ever Dr Leonard Post, Senior Vice President, Research & Development, enough? Onyx Pharmaceuticals Prof Ian Judson, Professor, Cancer Pharmacology, Honorary Consultant Medical Oncologist, Institute of Cancer Research / Royal Marsden NHS Trust 5.00 Chairman’s Closing Remarks and Close of Day One www.smi-online.co.uk/cancerdrugs.asp Register online and receive full information on all of SMi’s conferences Alternatively fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

8.30 Re-registration & Coffee 12.40 Lunch

9.00 Chairman’s Opening Remarks MULTIPLE ANTI-CANCER DRUGS WITH NOVEL MECHANISMS Prof Jim Cassidy, Professor, Oncology, Cancer Research UK, OF ACTION Medical Oncology 2.00 A clinically validated target, the mitotic spindle FUNCTIONAL GENOMIC APPROACH • Role of mitotic kinesins in cell division • Transcriptional profiling demonstrating the over expression of

11th March 2003 March 11th GENES-TO-DRUGS kinesin spindle proteins (KSP) in cancer 9.10 Exploiting the commercial potential of the 2001 Nobel Prize • Biochemical studies of KSP enzymatic inhibition in Medicine • Breadth of anti-tumour activity • Cell cycle biology pathways and checkpoint control • Mechanism-based anticancer drug design • Absence of treatment-associated neuropathy • Preclinical data Day Two Day Two • CDK Inhibitors: an emerging class of anticancer Rx • Alternative approaches targeting cyclin inhibition Dr Pearl Huang, Director, Oncology, GlaxoSmithKline • The Mitosis pathway and G2/M-specific drug design • Implications of the new paradigm for companies and investors EXPLOITING THE IMMUNE RESPONSE Spiro Rombotis, Chief Executive Officer, Cyclacel

TARGETED MOLECULAR THERAPY CANCER CELL-SPECIFIC MONOCLONALS WITH TOXIC PAYLOADS TARGETED TREATMENTS 2.40 Toxic drugs 9.40 Is the era of cytotoxics over? • Mechanism of action • Targeting treatment with cytotoxics • Technological procedures • Have targeted treatments lived up to their expectations? • Toxicology issues • Development of new cytostatic targeted treatments Dr Paolo Paoletti, Vice President, Medical – Oncology, ALIMTA • Regulatory matters Product Team Leader, Lilly • Preclinical data • Advantages of the technique SIGNAL TRANSDUCTION INHIBITION • Pitfalls to be overcome 10.20 Protein kinase inhibitors with broad therapeutic potential Dr Steve Holmes, Vice President, Antibody Discovery, Oxford • Mechanism of action at the molecular level GlycoSciences • Rational design - a challenge for a medicinal chemist • Preclinical profile at the enzymatic, cellular and in vivo level • Clinical data 3.20 Afternoon Tea • Successes and failures • Future challenges CANCER VACCINE STRATEGIES Dr Peter Traxler, Senior Scientist, Research Manager, Novartis 3.40 An overview • Review of vector platforms for therapeutic vaccines 11.00 Morning Coffee • Autologous vaccines DNA REPAIR: NEW TARGETS FOR CANCER THERAPY • Recombinant vaccines 11.20 Drugs as inhibitors of DNA repair • Naked antibodies • Biochemical and genetic methods for validating drug targets • Radioactive conjugates • Detection, signalling and repair of DNA double strand breaks • Combination treatments (DSB) • Encouraging results in early phase cancer vaccine clinical trials • Targeting the homologous recombination system and the non- homologous end joining (NHEJ) systems Dr Jeffrey Ulmer, Senior Director, Chiron • Inhibiting key enzymes in DNA DSB repair pathways • Enhancing the efficacy of chemotherapeutic agents and of ANTIBODIES TO MODULATE TUMOUR IMMUNITY ionising radiation therapy 4.20 Using tumour antibodies as vaccines • Potential anti-cancer activity of DNA repair inhibitors • Technology overview Prof Stephen Jackson, Deputy Director, Wellcome Trust / • Traditional use of monoclonal antibodies in cancer treatment Cancer Research UK Institute • Unexpected discovery of therapeutic potential for low dose POLYKETIDE DRUG CANDIDATES monoclonal antibodies 12.00 Epothilone D and Geldanamycin as anti-cancer agents • Mechanisms of immune activation by monoclonal antibodies • I. Manipulating the genetic instructions for making polyketides via immune complex formation • II. Production and properties of Epothilone D • Documented preclinical and clinical proof of principle • Clinical trials of epothilones • Broad therapeutic potential • III. Hsp90 as a drug target • Geldanamycin analogs as chemo-sensitizers Dr Birgit Schultes, Executive Director, Research, AltaRex Prof Dan Santi, Chairman, Chief Executive Officer, Kosan Biosciences 5.00 Chairman’s Closing Remarks and Close of Conference

SPONSORSHIP AND EXHIBITION OPPORTUNITIES SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company's marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call: Dale Butler, SMi Sponsorship on +44 (0)20 7827 6044 or email:[email protected] PHARMACEUTICAL FORWARD PLANNER www.smi-online.co.uk/pharma.asp Novel NOVEMBER 2002 • 06/07 Vaccines Immunotherapeutic • 18/19 Wholesale Distribution in the Pharmaceutical Industry • 18/19 Tissue Engineering Vaccine Platform DECEMBER 2002 12th March 2003, The Hatton, London • 02/03 Clinical Trials in CNS • 04/05 Dermatological Disorders In association with: JANUARY 2003 • 13/14 Portfolio Management in Pharmaceutical R&D About the Briefing • 15/16 Nutraceuticals, Functional Foods & Probiotics • 20/21 Reducing the Attrition Rate in Drug Discovery The Briefing will describe two approaches to cancer therapy under development at Biovex. In the first Biovex is developing • 27/28 Beyond the Genome dendritic cell-mediated anti-cancer vaccines using modified • 27/28 Computer Systems Validation in the herpes simplex virus (HSV) for antigen delivery. In the second Pharmaceutical Industry Biovex has developed an enhanced potency ‘oncolytic’ version of

HALF DAY EXECUTIVE BRIEFING HALF DAY HSV (ie it replicates selectively to kill tumour cells) combined FEBRUARY 2003 with expression of GM-CSF. The background and rationale for • 10/11 Microarray Technology: Commercial and each will be discussed, together with results so far. Technical Issues • 12/13 Antisense Technologies Briefing Timetable • 17/18 Angiogenesis • 17/18 Obesity and Related Disorders 9.00 Registration & Coffee • 24/25 Drug Design 9.30 GENERAL INTRODUCTION TO IMMUNOTHERAPY MARCH 2003 • Review of approaches to immunotherapy • 05/06 Superbugs & Superdrugs • Rationale behind the use of immunotherapeutic vectors • 10/11 Cancer Drug Development: New Directions and • Dendritic cell approach Challenges Dr Philip Reay • 17/18 Cosmetics and Healthcare • 19/20 Asthma Therapeutics 10.00 CONSTRUCTING A NOVEL IMMUNOTHERAPEUTIC VECTOR PLATFORM • 26/27 Predictive In Silico Models in Drug Discovery • Challenges of loading dendritic cells with therapeutic antigens and Development • Optimisation of HSV as a vector • 31/3-1/4 Biologics • High efficiency dendritic cell transduction APRIL 2003 • Multiple antigen delivery • Dendritic cell activation • 7/8 Target Validation Dr Robert Coffin • 9/10 Kinases • 28/29 Anti-arthritic Agents 10.30 PROGRESS TO DATE • 30/4-1/5 Supergenerics and Patent Busting • Choosing therapeutic antigen genes • The melanoma vaccine construct MAY 2003 • Planned proof-of-principle Phase I/II trials • 12/13 Drug Discovery • Further products for tumour antigen-encoding • 19/20 Gynaecological Medicine genes • 21/22 Paediatric Medicine • Potential additional targets in cancer and infectious disease JUNE 2003 Dr Philip Reay • 11/12 Pain Therapeutics • 23/24 Depression and Anxiety 11.00 Morning Coffee • 23/24 Outsourcing in the Pharmaceutical Industry 11.20 ONCOLYTIC CANCER THERAPY • 25/26 Neurodegenerative Disorders • Background and rationale • 30/6-1/7 Clinical Trials in Cancer • The in situ tumour vaccine concept • 30/6-1/7 Therapeutic Antibodies • OncoVEX GM-CSF: pre-clinical and clinical studies Dr Robert Coffin

Supported by 12.00 GENERAL DISCUSSION Close of Executive Briefing

Pre-registered delegates will be sent materials of interest prior to the Briefing. For this reason delegates are Pharma-i.com is the only community for the pharma- encouraged to register early. ceutical, biotechnology, healthcare and related life sciences professional live on the Internet. This unique site features a About your Briefing Leaders rich mix of pharmaceutical industry news, drug research, clinical trial updates, product news, an events diary, the Dr Philip Reay joined BioVex in August 2001 as Group latest market research, discussion forums, e-commerce Leader, Immunology. Prior to this Dr Reay was a Wellcome Senior Research Fellow in the Nuffield centres, and much more... Department of Clinical Medicine and the Molecular Immunology Group at the University of Oxford. Our 6,000 regular users include: Eli Lilly, Procter & Gamble, Novartis, Aventis, Pfizer, Parke-Davis, GSK, Merck & Co., Dr Robert Coffin, Chief Scientific Officer, is a Roche, Abbott Laboratories, AstraZeneca, Bristol-Myers founding scientist and Lecturer in Virology at Squibb, Boehringer-Ingelheim, ICN Pharmaceuticals, Bayer, University College London, and Honorary Senior Solvay, Sanofi-Synthelabo, Ortho-McNeil, Yamanouchi, Byk Lecturer at The Institute of Child Health. Dr Coffin has Gulden, Rhone-Poulenc, Teva Pharmaceutical, Whitehall- authored some 40 scientific papers and is an inventor Robins, Bayer, Servier Laboratories, Knoll, Janssen, Schering on 13 filed patent applications. Health Care, Ipsen Limited, Du Pont Pharma, McNeil About BioVex Consumer Healthcare, BioSante, and Genesis. Users include a wide range of senior executives in: clinical research, drug BioVex is a three year old private biotech company that is developing design, drug discovery, validation, lab equipment, a new class of potent vaccines principally to treat and prevent cancer. compliance, quality assurance, regulation, licensing, drug The Company is headquartered in Oxford, UK. delivery, gene therapy, biotechnology, pharmacoeconomics, The Company has three technology platforms based on the bioinformatics, proteonomics, nutraceuticals, wholesale/ manipulation of the herpes simplex type one virus. The Company has two vaccine platforms; OncoVEX and ImmunoVEX and a functional distribution, sales/marketing, CROs, active ingredients, and genomics platform for gene determination in the nervous system medical devices. (NeuroVEX). Want to know how you can get involved? Interested in The Company’s lead product OncoVEX GM-CSF is currently undergoing promoting your pharmaceutical services to this market? a Phase I/II study in breast cancer, head and neck cancer, gastro- intestinal cancer and malignant melanoma. Call Frances Denny, SMi Marketing on The Company’s ImmunoVEX vaccine platform stimulates a key class of +44 (0)20 7827 6110 or email: immune policing (dendritic) cells. The Company’s lead product to treat [email protected] malignant melanoma is expected to enter the clinic in the third quarter of 2003. SPONSORSHIP OPPORTUNITIES Please register the following delegates for (photocopy for multiple registrations) REGISTRATION FORM Dale Butler, SMi Sponsorship on Cancer Drug Development: +44 (0)20 7827 6044 or Conference: 10th & 11th March 2003 New Directions and Challenges email: [email protected] Executive Briefing: 12th March 2003 MARKETING OPPORTUNITIES 10th & 11th March 2003, The Hatton, London Frances Denny, SMi Marketing on +44 (0)20 7827 6110 or 50% DISCOUNT email: [email protected] Academic Researchers will receive EXECUTIVE PACKAGES 50% discount on marked price For our Executive package inclusive of a discount of £100, tick below: Proof of status to be sent with registration □ Option A Conference & Executive Briefing Fee: £1498.00 VAT: £262.15 Total: £1760.15 Unique Reference Code □□□□□□□□□□□□ Tick here for either the conference or executive briefing but not both: □ Option B Conference only Fee: £1099.00 VAT: £192.33 Total: £1291.33 □ Option C Executive Briefing only Fee: £499.00 VAT: £87.33 Total: £586.33 ACADEMIC DISCOUNT □ Option D Conference only Fee: £549.50 VAT: £96.16 Total: £645.66 How to register: By mail: Complete and return your signed Registration Form together with your cheque to: SMi Conferences Ltd, 1 New Concordia Wharf, Mill St, London, SE1 2BB By fax: Complete and fax your signed Registration Form with your credit card details to +44 (0)870 9090 712

LVK21 web:pdf LVK21 By internet: Complete your Registration Form online with your credit card details at www.smi-online.co.uk/cancerdrugs.asp

Your purchase order no □□□□□□□□□□□□ How to contact us: Telephone: +44 (0) 870 9090 711 PLEASE USE BLOCK PRINT - PLEASE COMPLETE FORM IN FULL Fax: +44 (0) 870 9090 712 □□□□□□□□□□□□□□□□□ Email: [email protected] Title Web: www.smi-online.co.uk/cancerdrugs.asp Forename □□□□□□□□□□□□□□□□□ Initials □□□□□□□□□□□□□□□□□ How we will contact you: SMi Conferences Ltd’s preferred method of communication is by email and phone. Please ensure you complete the Registration Form so that we can contact Surname □□□□□□□□□□□□□□□□□ you. We will use postal services on a request basis only. Department □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ Venue: The Hatton, 51-53 Hatton Garden, London, EC1N 8HN. Job Title The Hatton is SMi Conferences Ltd’s bespoke state of the art conference venue and has □□□□□□□□□□□□□□□□□□□□ excellent transport links to all London airports, with train and tube stations nearby. There are Organisation □□□□□□□□□□□□□□□□□ also three NCP car parks in close proximity. Full details will be included in your conference □□□□□□□□□□□□□□□□□□□□ joining pack. Address □□□□□□□□□□□□□□□□□ SMi can arrange your accommodation at the best possible rates. The SMi Travel Team are □□□□□□□□□□□□□□□□□□□□ available to make your stay during the conference as hassle free and as smooth as possible. Please contact us on +44 (0) 870 9090 713 fax +44 (0) 870 9090 714 □□□□□□□□□□□□□□□□□□□□ email: [email protected] or visit our website www.smi-online.co.uk/travel.asp Town/City □□□□□□□□□□□□□□□□□ Please book early to get the full advantage of our accommodation packages. County □□□□□□□□□□□□□□□□□ Payment terms: SMi Conferences Ltd require the full amount to be settled prior to the event taking place. SMi Conferences Ltd reserves the right to refuse entry to any customer who has not paid their invoice. A credit card guarantee may be Post/Zip code□□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□ requested if full payment has not been received. Country Methods of payment: Payment must be in sterling. You can pay by cheque drawn on a UK bank, payable to SMi Conferences Direct Phone □□□□□□□□□□□□□□□□□ Ltd or by bank transfer to HSBC Account No: 11364057 Sort Code: 40 06 21 (For overseas customers please use SWIFT CODE MIDLGB22) 28 Borough High St, London SE1 1YB, or by credit card. Please complete the Registration Form. When making Direct Fax □□□□□□□□□□□□□□□□□ payments please quote delegate’s name and conference and/or product. Switchboard Phone □□□□□□□□□□□□□□□ Interest: SMi Conferences Ltd reserves the right to charge interest on any unpaid invoices. Switchboard Fax □□□□□□□□□□□□□□□ Alteration to invoices: Any alterations to an invoice, excluding substitutions/names changes, requested by the customer will incur an administration fee of £50 and will be charged to the customer by credit card prior to the amendment being made. Email □□□□□□□□□□□□□□□□□ □□□□□□□□□□□□□□□□□□□□ Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post, fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the Booking Contact □□□□□□□□□□□□□□□ conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes which are available on the day will be sent to you. Job Title □□□□□□□□□□□□□□□□□ Unfortunately we are not able to transfer places between conferences and conferences and executive briefings. However, if □□□□□□□□□□□□□□□ you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in Immediate Manager writing by email, fax or post. Name changes and substitutions must be from the same company and are not transferable Business Sector □□□□□□□□□□□□□□□□ between companies or countries. Number of employees on site □□□□□□□□□□□□ Indemnity: SMi Conferences Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of SMi Conferences Ltd. If such a situation arises we will endeavour to reschedule the event. However, SMi Conferences Ltd cannot be held responsible for any cost, damage or Signature Date expenses which may be incurred by the customer as a consequence of the event being postponed or cancelled. I agree to SMi Conferences Ltd Terms and Conditions of Booking. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.

I cannot attend the conference but wish to purchase: Data Protection: SMi Group Ltd gathers and manages data in accordance with the Data Protection Act 1988. The □ information about you contained on this form may be used to update you on SMi Group products and services via post, £300 Documentation (including postage and packing) telephone, fax or e-mail, unless you state that you do not want us to do so. We may also share your data with external □ £500 Documentation and Audio Tapes (including VAT, postage and packaging) companies offering complementary products or services. If you wish for your details to be amended, suppressed or not To order, complete the Registration Form and complete your method of passed on to any external third party, please send your request to Database Manager, SMi Group Ltd, No 1 New Concordia payment. Payment must be received before the goods can be despatched Wharf, Mill Street, London, SE1 2BB. Alternatively, you can visit our website www.smi-online.co.uk/updates and amend your which will be 7-14 days after the conference. details. When you inform SMi Group Ltd of any updates or queries, please ensure you include the 8 digit “unique reference number”. Please allow approximately 30 days for your removal or update request to be applied to our database. Following PAYMENT: your removal or update request, you may receive additional pieces of communication from SMi Group during the transitional period, whilst the changes are applied. □ I enclose a cheque (drawn on a UK Bank made payable to SMi Conferences Ltd) □ I am transferring the money to HSBC Bank plc, Account No: 11364057, The fee includes lunch, refreshments and conference papers provided on the day. It does not include travel, hotel accommodation, transfers or insurance (which we strongly recommend you obtain). Sort Code: 40 06 21 (For overseas customers please use SWIFT CODE MIDLGB22) 28 Borough High Street, London SE1 1YB VAT will be charged at the local rate on each conference. Delegates may be able to □ Please debit my credit card (including % & tax) recover VAT incurred by contacting Eurocash Corporation plc (0)1273 325000, □ □ Visa/MasterCard (1.90%) Amex (3.80%) [email protected]. Eurocash are specialists in recovering cross border VAT. □ Diners (3.00%) □ Eurocard (1.90%)

Card No □□□□□□□□□□□□□□□□ Expiry Date □□□□

Signature Date I agree to SMi Conferences Ltd Terms and Conditions of booking and SMi debiting my credit card. If you have NOT received registration confirmation within 48 hours of registering, please call +44 (0) 870 9090 711